SCHEMBL953761

SCHEMBL953761

Cc1nn2ccccc2c1-c1nc(C2CCOCC2)c(C(N)=O)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.36
ATR Q13535 1/20 0.36
PDCD1 Q15116 1/20 0.36
ATRIP Q8WXE1 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
CNR1 P21554 2/20 0.36
NTRK1 P04629 2/20 0.36
TSHR P16473 1/20 0.35
PIK3CD O00329 2/20 0.35
PIK3CB P42338 2/20 0.35
PIK3CG P48736 1/20 0.35
PDE4B Q07343 2/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
PDE10A Q9Y233 1/20 0.34
HTR2C P28335 1/20 0.33
MAPK1 P28482 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
IKBKB O14920 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL952323 0.91 CNR1 (0.39) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL953958 0.90 TSHR (0.42) CNR1TSHRPDE4BMAPK9MAPK10
SCHEMBL954029 0.87 ALDH1A1 (0.42) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL955453 0.81 TSHR (0.42) CNR1TSHRPDE4BMAPK9MAPK10
SCHEMBL953767 0.77 TSHR (0.43) TSHRLMNA
SCHEMBL16937941 0.77 CHEK1 (0.35) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL952241 0.77 CDC7 (0.52) MAPK1LMNACYP1A2CYP3A4CYP2C19
SCHEMBL958143 0.77 LMNA (0.38) TSHRPDE4BLMNACYP1A2CYP3A4
SCHEMBL953497 0.77 CDC7 (0.39) TSHRPDE4BHTR2CLMNACYP1A2
SCHEMBL6842656 0.76 CHEK1 (0.34) CHEK1ATRPDCD1ATRIPCD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CHEK1 812/4885ATR 1442/4885PDCD1 1289/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CHEK1 913/4885ATR 2022/4885PDCD1 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.